Sagimet Biosciences Shares Rise After Positive Phase 3 Safety Data for Acne Drug

Sagimet Biosciences (NASDAQ: SGMT) shares moved higher after the company’s China partner, Ascletis Pharma, reported positive topline results from a long-term Phase 3 safety study of denifanstat in patients with moderate-to-severe acne.

Key takeaways:

• A Phase 3 open-label trial showed denifanstat was generally well tolerated over 40 weeks in moderate-to-severe acne patients.
• Only two categories of treatment-emergent adverse events were reported in more than 5% of patients: dry eye syndrome (5.5%) and dry skin (5.2%).
• Prior Phase 3 data in a larger randomized study reportedly met primary and secondary endpoints, strengthening confidence ahead of regulatory discussions.
• Denifanstat’s fatty acid synthase (FASN) inhibition mechanism continues to attract attention as a potential new approach in acne, while Sagimet pursues development for MASH outside China.

The open-label Phase 3 study evaluated Ascletis’ ASC40 (denifanstat) tablets for safety over a 40-week period in acne patients. Denifanstat is being developed by Ascletis for acne in China, while Sagimet is advancing the same molecule for metabolic dysfunction–associated steatohepatitis (MASH) in the rest of the world.

From a safety standpoint, the topline readout was straightforward: denifanstat was described as generally well tolerated, with drug-related adverse events characterized as mild or moderate and no permanent discontinuations due to adverse events. The most common treatment-emergent adverse events occurring in more than 5% of patients were dry eye syndrome (5.5%) and dry skin (5.2%), which are consistent with the kinds of tolerability signals investors expect to see monitored closely in longer-duration dermatology studies.

Management highlighted that the additional long-term dataset adds confidence in the broader clinical profile of FASN inhibition in acne. The update also follows earlier Phase 3 results from Ascletis, which the company previously said met primary and secondary endpoints in a 480-patient randomized, double-blind, placebo-controlled trial in moderate-to-severe acne.

For investors, the key question is how these safety results translate into the next regulatory steps in China and how they may inform broader valuation expectations for denifanstat as an asset. While Sagimet’s primary focus remains MASH outside China, positive safety and efficacy signals in a separate, commercially relevant indication can strengthen the overall narrative around the molecule and its mechanism of action.